Search results
Showing 1201 to 1215 of 1335 results for primary care
Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)
Evidence-based recommendations on venetoclax (Venclyxto) with rituximab for previously treated chronic lymphocytic leukaemia in adults.
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)
Evidence-based recommendations on etranacogene dezaparvovec (Hemgenix) for treating moderately severe or severe haemophilia B in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with chemotherapy before surgery (neoadjuvant) and then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults
NICE has developed a medtech innovation briefing (MIB) on AlignRT in breast cancer radiotherapy .
Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)
Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant.
Evidence-based recommendations on pemigatinib (Pemaryze) for relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.
practice was unclear because of subsequent improvements in perioperative care such as better preoperative risk assessment and...
Evidence-based recommendations on nintedanib (Vargatef) for treating locally advanced, metastatic or locally recurrent non-small-cell lung cancer in adults.
Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]
Discontinued [GID-TA10065]
Roflumilast for treating chronic obstructive pulmonary disease (TA461)
Evidence-based recommendations on roflumilast (Daxas) for treating chronic obstructive pulmonary disease in adults with chronic bronchitis.
Evidence-based recommendations on atezolizumab (Tecentriq) with nab-paclitaxel for triple-negative, unresectable, PD-L1-positive, locally advanced or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]
Discontinued [GID-TAG393]
Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]
Discontinued [GID-TA10070]